MyoKardia Inc. priced an underwritten public offering of 3.5 million common shares at $35.50 apiece.
The company also granted underwriters a 30-day option to buy up to an additional 525,000 common shares on the same terms and conditions.
The offering is expected to close on or around Aug. 14, subject to customary closing conditions.
MyoKardia plans to use net proceeds to help fund research and development activities for its development activities, as well as for working capital and general corporate purposes.
J.P. Morgan Securities LLC and Cowen and Co. LLC are acting as joint book-running managers for the offering, with BMO Capital Markets Corp. as book runner and Wedbush Securities Inc. as co-manager.